MedTrace Logo

Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities

NCT00628576 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2008-03-05

No results posted yet for this study

Summary

The purpose of the study was to evaluate efficacy and safety of the new acute treatment of deep venous thrombosis by use of low-molecular-weight heparin compared with standard treatment using unfractionated heparin, especially concerning long-term morbidity.

Conditions

  • Deep Venous Thrombosis

Interventions

DRUG

unfractionated heparin

UFH: Continuous i.v. infusion 100 IU/kg/4hrs initially and then adjusted to maintain APTT value 1.5 - 2.5 the pre-treatment value

DRUG

Tinzaparin (Leo)

FH (Tinzaparin): 175 iu/kg s.c. in the abdomen once daily

Sponsors & Collaborators

  • Aalborg University

    collaborator OTHER

  • Aalborg University Hospital

    lead OTHER

Principal Investigators

  • Benedicte Laursen, MD, DMSc · Department of Haematology; Aalborg Hospital, 9100 Aalborg, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-10-31
Primary Completion
2004-06-30
Completion
2004-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00628576 on ClinicalTrials.gov